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Abstract
Background: Mitochondrial DNA (mtDNA) is known for high mutation rates caused by lack of
protective histones, inefficient DNA repair systems, and continuous exposure to mutagenic effects
of oxygen radicals. Alterations in the non-coding displacement (D) loop of mitochondrial DNA are
present in many cancers. It has been suggested that the extent of mitochondrial DNA mutations
might be useful in the prognosis of cancer outcome and/or the response to certain therapies. In
order to investigate whether a high incidence of mutations exist in mitochondrial DNA of cervical
cancer patients, we examined the frequency of mutations in the D-loop region in 19 patients of
cervical cancer.
Results: Mutations, often multiple, were detected in 18 of 19 (95%) patients. The presence of
mutations correlated with Human Papilloma Virus (HPV) infection in these patients. Mutations
were also detected in normal samples and lymphocytes obtained from cervical cancer patients, but
their frequency of occurrence was much lower as compared to the cervical cancer tissues.
Conclusion: Our findings indicate that D-loop alterations are frequent in cervical cancers and are
possibly caused by HPV infection. There was no association of mtDNA D-loop mutations with the
histopathological grade and tumor staging.
Background
The human mtDNA is a double stranded circular mole-
cule of 16569 bp and contains 37 genes coding for two
rRNAs, 22 tRNAs and 13 polypeptides. It is present in high
copy numbers (103–104 copies per cell) in virtually all
cells and the vast majority of copies are identical at birth.
Furthermore, mtDNA is known for having high acquired
mutation rates which are 10 times higher than that of
nuclear genomic DNA. It is generally accepted that high
mutation rates of mtDNA are caused by lack of protective
histones, inefficient DNA repair systems and continuous
exposure to mutagenic effects of oxygen radicals generated
by oxidative phosphorylation [1]. An association between
mtDNA mutations and neurologic or metabolic disorders
has previously been reported [2-4].
The D-loop, which is 1124 bp in size (positions 16024-
576), is a non-coding region, and acts as a promoter for
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Table 1: Novel mutations detected in the mitochondrial D-loop region of cervical cancer tissues, controls and lymphocytes
Tumors Controls
Base pair Mutation No. of samples Base pair Mutation No. of samples
65 A insertion 1 5 T-C 1
105 C deletion 1 56 A-T 1
134 T-A 1 60 T deletion 1
144 C-T 1 303 A insertion 1
151 A insertion 1 311 A insertion 1
179 T-C 1 319 T insertion 1
224 T-C 1 323 C insertion 1
268 A insertion 1 336 A insertion 1
269 T insertion 1 337 A insertion 1
295 A insertion 1 343 T insertion 1
311 A insertion 1 371 C-A 1
317 C-T 1 375 A insertion 1
371 C-A 1 420 A insertion 1
378 C-T 1 427 A insertion 1
412 C-A 1 456 T insertion 1
424 T insertion 1 563 A-G 1
424 T-A 1 16184 T insertion 1
484 A-G 1 16189 T deletion 1
511 C-T 2 16318 A insertion 1
519 A-G 1 16333 A-T 1
563 A-G 1 16335 A insertion 1
16027 T-C 1 16356 A insertion 1
16045 T-A 1 16542 A insertion 1
16045 T insertion 1
16064 T-A 1 Lymphocytes
16068 T insertion 1 Base pair Mutation No. of samples
16068 T-A 1 29 A-C 1
16070 T insertion 1 61 A insertion 1
16073 C-A 1 65 T-A 1
16092 T deletion 1 379 A-C 1
16095 A insertion 1 16036 C insertion 1
16123 A insertion 1 16038 A-G 1
16137 A deletion 1 16065 G-A 1
16143 T deletion 1 16067 A insertion 1
16157 T-A 1 16109 T insertion 1
16170 A deletion 1
16177 A-G 1
16180 A deletion 2
16212 A insertion 2
16214 A insertion 2
16215 T deletion 2
16220 A deletion 1
16222 C deletion 1
16225 C-T 1
16289 T insertion 1
16293 A deletion 1
16367 A deletion 1
16381 C insertion 2
16383 T insertion 1
16396 C insertion 2
16402 C insertion 1
16405 C insertion 1
16406 T insertion 1
16408 C insertion 1
16413 T insertion 1
16414 T insertion 1
16420 A deletion 1
16428 C insertion 1
16434 A insertion 1Cancer Cell International 2005, 5:34 http://www.cancerci.com/content/5/1/34
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both the heavy and light strands of the mtDNA, and con-
tains essential transcription and replication elements. The
D-loop region is a hot spot for mtDNA alterations, and it
contains two hypervariable regions (HV1 at positions
16024–16383 and HV2 at positions 57–372). The
sequence analysis of these two regions is used not only in
forensic analyses, but also in medical diagnosis [5].
Mutations in the mtDNA have been reported to occur in
human cancers [6-11]. Alonso et al [7] detected mutations
in the mtDNA D-loop region in colorectal and gastric
malignancies. There are other reports that have analyzed
alterations of the D-loop in lung cancer, colon cancer,
ovarian cancer, hepatocellular carcinoma and breast can-
cer [12-16].
Cervical cancer is a leading cause of cancer related death
in females and is the second most common gynecologic
malignancy worldwide [17]. Developing countries
account for the majority (80%) of the 500,000 new cases
diagnosed each year as well as for the significant propor-
tion of the mortality (80%) [18]. Squamous cell carcino-
mas are the most common histologic type followed by
adenocarcinomas and other rarer types in cervical cancer.
The major biological risk factor implicated in the develop-
ment of cervical cancer is the human papilloma virus
(HPV). The causal role of human papillomavirus infec-
tions in cervical cancer has been verified by epidemiologic
criteria, and HPV DNA has been shown to be present in
over 91% of squamous cell carcinomas of the cervix [18].
In this study, we examined alterations of the D-loop
region in cervical cancer tissues, and related our findings
to clinicopathological features and HPV infection.
Results and discussion
The purpose of this study was to evaluate the mutation
frequencies in the two hypervariable regions (HV1 and
HV2) and the region between the two hypervariable
regions of the mtDNA D-loop in cervical cancer, and the
correlation of these mutations with HPV infection. Nine-
teen patients with cervical cancer were included in the
study.
While mitochondrial DNA mutations have been studied
widely in the context of rare genetic diseases, their
involvement in carcinogenesis has been relatively less
studied [19]. Since mitochondria is the site of initiation of
apoptosis, therefore, mutation of its genome may play a
causative role in cancer. The reports that do exist on the
subject appear inconsistent or at times contradictory e.g.
Heerdt et al [13] found no mutations in the promoter for
the H and L strands on the mtD-loop region, in a study
done to determine a possible association with colon can-
cer. However, another report showed that 70% of the
colon cancers examined displayed mitochondrial DNA
mutations [20]. Among other tumor types studied,
Tamura et al [8] analyzed the mutations of the mtDNA D-
loop region including HV1 and HV2 in 45 Japanese
patients with gastric cancer, and found mutations in 4%
of the tumors. Conversely, Alonso et al [7] detected muta-
tions in the mtDNA D-loop region in 23% colorectal
tumors and 37% gastric tumors. Fliss et al [11] analyzed
mutations in mtDNA in bladder, head and neck, and lung
cancer and found mutations in 50% of cancers of which
67% were in the mtDNA D-loop region.
To the best of our knowledge, this is the first report to
examine the involvement of mitochondrial mutations in
cervical cancer. Except for one study [21], apparently, the
involvement of mtDNA mutations in cervical cancer has
not been examined. A search of literature failed to turn up
any relevant studies. Hence, this study is a step in this
direction. Mitochondrial mutations have been reported in
other gynecological malignancies. In ovarian cancer 60%
of somatic mutations in the D loop, 12 s rRNA, 16 s rRNA
and cyt b have been reported [14]. Most of the mutations
were T → C or G → A transitions. The only report on
mtDNA mutations in cervical cancer has reported high
frequency of D310 mutations in 35% of cases [21]. How-
ever, they have not looked at other mtDNA mutations
besides D310.
We examined 19 cervical cancer tissues and found that
95% samples showed mutation within a 1 Kb region of
the 16 Kb genome that we examined. If the same variation
appeared in both cancer and normal tissue, it was consid-
ered as polymorphism. We also found mutations in the
normal tissues and lymphocytes that we examined, but
their frequency was lower than that observed in case of
tumors. Most of the mutations in both normal and tumor
DNA were single base substitutions along with insertions
and deletions. We found novel mutations at 55 sites in
case of tumors. Similar mutations were found in more
than one sample. In case of controls, only 23 sites had
these novel mutations whereas these mutations were
present at only 9 sites in lymphocytes [Table 1]. Interest-
ingly, the presence of mutations correlated significantly (p
< 0.05) with HPV infection.
Furthermore, we noted a high rate of polymorphism in
the DNA obtained from both normal and tumor tissue.
We found polymorphisms at 81 sites in tumors, at 26 sites
in controls and at 13 sites in lymphocytes.
A high frequency of mitochondrial microsatellite instabil-
ity (mtMSI) was detected in the D-loop region in these
samples. We observed mtMSI in two different regions,
including CA repeats of nucleotide positions 514–523
within a nonfunctional D-loop sequence (1/19) and aCancer Cell International 2005, 5:34 http://www.cancerci.com/content/5/1/34
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common homopolymeric C stretch interrupted by a T
(CCCCCTCCCC) at nucleotide positions 303–315 (11/
19). The mtMSI within the mononucleotide repeat at
nucleotide position 303–309 has been frequently
observed in endometrial tumors [21]. This mtMSI has also
been detected in ovarian carcinomas [14]. This region is
part of the binding site of replication primer. Variation in
the CA repeats was detected in only one of the cervical car-
cinoma samples. Instability of the CA repeats has also
been seen at a low frequency in endometrial [22], ovarian
[14], gastric cancers [23] and glioblastoma [24]. However,
there is a significantly higher frequency of the CA-repeat
instability in breast cancer (42.5%) [25]. On the basis of
these findings, we suggest that somatic mtMSI occurs dif-
ferentially in different tumors.
Malfunctions of mismatch repair genes have been associ-
ated with nuclear MSI. However, to date, no mismatch
repair genes have been found responsible for the mainte-
nance of mammalian mitochondrial genome. The occur-
rence of high frequency of mtMSI in cervical cancers
indicates that DNA repair in mitochondria is highly inef-
ficient after malignant transformation with HPV. The dif-
ferent frequencies of occurrence of the mtMSI at the
mononucleotide repeat at nucleotide position 303–315
in different tumor cell types suggests that deficits in mis-
match repair function in mitochondria may vary from one
tumor to another.
The occurrence of mtMSI may derive mainly from errone-
ous replication, whereas point mutations may be attrib-
uted to oxidative damage caused by reactive oxygen
species. In addition, a study [26] suggests that homopoly-
morphic nucleotide tracts in mtDNA are error prone
because of the low frameshift fidelity of the DNA
polymerase gamma that carries out the mtDNA replica-
tion. Thus, mtMSI in cervical cancers may be mainly
attributed to errors of replication. Moreover, there is sup-
portive evidence that there are cell-specific differences in
the repair of mtDNA damage [27]. The differential occur-
rence of mtDNA mutations in various cancers may be
partly due to the presence of different repair mechanisms
in different tumor cell types.
We also found novel polymorphisms at 11 sites in tumors
and at 4 sites in normal tissue [Table 2]. There was a sub-
stantial difference in the frequency of mutations between
patients in our study. The mutations detected ranged from
1 to 13 within the 1 kb region that we examined. We were
unable to draw any correlations between the number of
mutations and clinical characteristics.
Conclusion
The study indicates that mitochondrial mutations are
indeed frequent in cervical cancer cells and further work is
warranted in this direction. Further, given the critical role
of mitochondria in apoptosis, perhaps the mutations in
mtDNA in cancer cells could significantly affect the cellu-
lar apoptotic response to chemotherapeutic agents. How-
ever, we did not find any correlation between mtDNA
mutation and apoptotic index or apoptosis related pro-
and anti-apoptotic proteins (data not shown).
Methods
Sample collection and DNA extraction
A total of 24 surgically resected cervical tissue samples
obtained after informed consent from the Department of
Obstetrics & Gynecology, All India Institute of Medical
Sciences, New Delhi, India were collected and frozen at -
70°C. The age of the patients ranged from 29 yrs to 65 yrs
[Table 3]. None of them had received any prior radiation
therapy or chemotherapy. These samples consisted of 17
squamous cell carcinoma 1 adeno-squamons and 1 aden-
ocarcinoma, of the cervix, and 5 histopathologically nor-
mal cervical tissue obtained from women undergoing
hysterectomy for reasons other than cervical cancer [Table
Table 2: Novel polymorphisms detected in the mitochondrial D-loop of cervical cancer tissues and controls
Tumors Controls
Base pair Polymorphism No. of samples Base pair Polymorphism No. of samples
113 C-A 1 57 T-A 1
141 A insertion 2 113 C-A 1
268 C-A 1 268 C-A 1
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3]. Also, representative sections of cervical tissue were
stained with eosin and hematoxylin for confirmation of
diagnosis. The tumor samples contained at least 70% of
malignant cells. Lymphocytes were also obtained from
cervical cancer patients whose tumor tissues were col-
lected.
DNA isolation and analysis
Total DNA (nuclear and mitochondrial) was isolated as
described earlier [18]. The samples were digested with
Proteinase K, extracted with phenol-chloroform, and eth-
anol precipitated. The quality of the DNA was checked by
PCR for β globin as an internal control. This DNA was
used to amplify the entire D-loop region of the mitochon-
drial genome known to have high mutation rates. The
region which spans sequences from 15964–16439 was
amplified using the forward and reverse primers as fol-
lows: 5'-AAAGTCTTTAACTCCACC-3' and 5'-GCACTCTT-
GTGCGGGATATTG-3'. The region from 16531-740 was
amplified with the following primers 5'-AAT-
AGCCCACACGTTCCCCT-3' and 5'-CGTGGTGATTTA-
GAGGGTGA-3'. The two fragments thus obtained were
cloned into the TA cloning vector pGEM-TEasy (Promega,
USA) and were subjected to sequencing using the M13
forward and reverse primers. Sequences were compared
against a mitochondrial data base [28]. Nuclease-free
water was used as a negative control for PCR instead of
DNA.
HPV testing was done as described earlier [18] using con-
sensus primers MY09/11 from the L1 region. The primer
sequences for HPV 16 primers were 5' CCC AGC TGT AAT
CAT GCA TGG AGA 3' and 5' GTG TGC CCA TTA ACA
GGT CTT CCA 3' and HPV-18 primers were 5'AAGGAT-
GCTGCACCGGCTGA 3' and 5' CACGCACACGCTT-
GGCAGGT 3'.
Statistical analysis
Correlation of presence of mitochondrial DNA mutations
with HPV infection was done using the chi-square test. A
p value < 0.05 was considered statistically significant.
Authors' contributions
HS carried out the experimental work, did BLAST
searches, analyzed data and drafted the manuscript. AS
collected the samples for the study and performed DNA
extraction. CS participated in the cloning of PCR products
in pGEMTEasy vector. SKJ provided the samples for the
Table 3: Clinicopathological features of patients included in the study, and presence of HPV infection.
Tumors
Case No. Age (Years) Stage H/P type Grade HPV type
3 65 IIb LCNK MD HPV-16
56 0I a L C N K M D n e g
62 9I a L C N K M D H P V - 1 6
12 40 Ib LCNK MD HPV-16
17 35 IIb LCNK MD HPV-16
18 50 Ia LCNK MD HPV-16
23 43 Ia KSCC MD HPV-16
24 42 IIIb LCNK MD HPV-16
28 48 IIb LCNK MD HPV-16
33 40 IIIb LCNK MD HPV-16
36 65 IIb LCNK PD HPV-16
38 35 IIb LCNK MD HPV-16
42 35 IIb LCNK PD HPV-16
50 38 IIa AS MD HPV-16
53 45 Ia LCNK MD HPV-16
56 35 Ia LCNK MD neg
60 35 Ib LCNK MD HPV-16
61 42 Ib AD MD HPV-16
62 47 Ib LCNK MD HPV-16
Controls
1 4 2 N AN AN An e g
2 5 5 N AN AN An e g
3 4 0 N AN AN An e g
4 5 0 N AN AN An e g
5 4 2 N AN AN An e g
H/P-Histopathological; NA-Not applicable; neg-negative; ND-Not determined;
LCNK-large cell non-keratizing; AS-Adenosquamous carcinoma; AD-Adenocarcinoma;
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